rec1  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC rec1
    CD37 expression in RAMOS and REC-1 tumors. ( A ) In vitro CD37 expression in <t>REC1</t> and RAMOS tumors determined by flow cytometry. CD37 expression is presented as mean fluorescent intensity (MFI). HCC827 lung adenocarcinoma cells were used as negative control. Data is shown as mean ± SD. ( B ) Hematoxylin and eosin staining and CD37 immunohistochemistry on formalin-fixed, paraffin-embedded REC1 and RAMOS tumor tissue sections. Representative tumors are shown.
    Rec1, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rec1/product/ATCC
    Average 94 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    rec1 - by Bioz Stars, 2022-09
    94/100 stars

    Images

    1) Product Images from "89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma"

    Article Title: 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma

    Journal: Scientific Reports

    doi: 10.1038/s41598-022-10139-6

    CD37 expression in RAMOS and REC-1 tumors. ( A ) In vitro CD37 expression in REC1 and RAMOS tumors determined by flow cytometry. CD37 expression is presented as mean fluorescent intensity (MFI). HCC827 lung adenocarcinoma cells were used as negative control. Data is shown as mean ± SD. ( B ) Hematoxylin and eosin staining and CD37 immunohistochemistry on formalin-fixed, paraffin-embedded REC1 and RAMOS tumor tissue sections. Representative tumors are shown.
    Figure Legend Snippet: CD37 expression in RAMOS and REC-1 tumors. ( A ) In vitro CD37 expression in REC1 and RAMOS tumors determined by flow cytometry. CD37 expression is presented as mean fluorescent intensity (MFI). HCC827 lung adenocarcinoma cells were used as negative control. Data is shown as mean ± SD. ( B ) Hematoxylin and eosin staining and CD37 immunohistochemistry on formalin-fixed, paraffin-embedded REC1 and RAMOS tumor tissue sections. Representative tumors are shown.

    Techniques Used: Expressing, In Vitro, Flow Cytometry, Negative Control, Staining, Immunohistochemistry, Formalin-fixed Paraffin-Embedded

    [ 89 Zr]Zr- N -sucDf-NNV003 PET imaging and ex vivo biodistribution in REC1 xenografted mice. ( A ) Representative coronal PET images of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 biodistribution in REC1 tumor-bearing mice at 1, 3 and 5 days (d) pi. [ 89 Zr]Zr- N -sucDf-NNV003 uptake is presented as standardized uptake value (SUV). The dashed circle indicates REC1 tumor. ( B ) Quantification of [ 89 Zr]Zr- N -sucDf-NNV003 uptake in REC1 tumor and blood pool activity at 1, 3 and 5 days pi. [ 89 Zr]Zr- N -sucDf-NNV003 uptake is presented as mean standardized uptake value (SUV mean ). TBR indicates tumor-to-blood ratio at day 5 pi. ( C ) Ex vivo biodistribution results of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 versus [ 111 In]In-DTPA-IgG control in REC1 tumor-bearing mice at 5 days pi. Tracer uptake per organ is presented as percentage of injected radioactivity dose per gram tissue (%ID/g). ( D ) Left: Ex vivo REC1 tumor uptake of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 versus [ 111 In]In-DTPA-IgG control at day 5 pi. Tumor uptake of tracer is presented as %ID/g. Right: Ex vivo tumor-to-blood ratio of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 versus [ 111 In]In-DTPA-IgG control in REC1 tumor-bearing mice at day 5 pi. Data in ( B – D ) is shown as mean ± standard deviation (SD). ** P
    Figure Legend Snippet: [ 89 Zr]Zr- N -sucDf-NNV003 PET imaging and ex vivo biodistribution in REC1 xenografted mice. ( A ) Representative coronal PET images of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 biodistribution in REC1 tumor-bearing mice at 1, 3 and 5 days (d) pi. [ 89 Zr]Zr- N -sucDf-NNV003 uptake is presented as standardized uptake value (SUV). The dashed circle indicates REC1 tumor. ( B ) Quantification of [ 89 Zr]Zr- N -sucDf-NNV003 uptake in REC1 tumor and blood pool activity at 1, 3 and 5 days pi. [ 89 Zr]Zr- N -sucDf-NNV003 uptake is presented as mean standardized uptake value (SUV mean ). TBR indicates tumor-to-blood ratio at day 5 pi. ( C ) Ex vivo biodistribution results of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 versus [ 111 In]In-DTPA-IgG control in REC1 tumor-bearing mice at 5 days pi. Tracer uptake per organ is presented as percentage of injected radioactivity dose per gram tissue (%ID/g). ( D ) Left: Ex vivo REC1 tumor uptake of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 versus [ 111 In]In-DTPA-IgG control at day 5 pi. Tumor uptake of tracer is presented as %ID/g. Right: Ex vivo tumor-to-blood ratio of 10 µg [ 89 Zr]Zr- N -sucDf-NNV003 versus [ 111 In]In-DTPA-IgG control in REC1 tumor-bearing mice at day 5 pi. Data in ( B – D ) is shown as mean ± standard deviation (SD). ** P

    Techniques Used: Positron Emission Tomography, Imaging, Ex Vivo, Mouse Assay, Activity Assay, Injection, Radioactivity, Standard Deviation

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • rec 1  (ATCC)
    94
    ATCC rec 1
    External beam RT synergizes with venetoclax to lengthen survival of mice bearing B-NHL xenografts Mice implanted with subcutaneous xenografts of A. <t>Rec-1</t> (MCL) or B. SU-DHL-6 (GCB-DLBCL) were treated with either drug diluent only (control), 8 or 10 Gy external beam 137 Cs irradiation (RT), venetoclax (daily for 21 days), or RT plus venetoclax, when tumors were ~50mm 3 ). N = 9–10 mice/group, additional statistics in text.
    Rec 1, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rec 1/product/ATCC
    Average 94 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    rec 1 - by Bioz Stars, 2022-09
    94/100 stars
      Buy from Supplier

    93
    ATCC s albus subsp
    Streptomyces albus <t>subsp.</t> <t>chlorinus</t> NRRL B-24108 (left) and Streptomyces albus subsp. chlorinus JR1 (right) spores on MS agar medium.
    S Albus Subsp, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s albus subsp/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    s albus subsp - by Bioz Stars, 2022-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    External beam RT synergizes with venetoclax to lengthen survival of mice bearing B-NHL xenografts Mice implanted with subcutaneous xenografts of A. Rec-1 (MCL) or B. SU-DHL-6 (GCB-DLBCL) were treated with either drug diluent only (control), 8 or 10 Gy external beam 137 Cs irradiation (RT), venetoclax (daily for 21 days), or RT plus venetoclax, when tumors were ~50mm 3 ). N = 9–10 mice/group, additional statistics in text.

    Journal: Cancer research

    Article Title: Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

    doi: 10.1158/0008-5472.CAN-17-0082

    Figure Lengend Snippet: External beam RT synergizes with venetoclax to lengthen survival of mice bearing B-NHL xenografts Mice implanted with subcutaneous xenografts of A. Rec-1 (MCL) or B. SU-DHL-6 (GCB-DLBCL) were treated with either drug diluent only (control), 8 or 10 Gy external beam 137 Cs irradiation (RT), venetoclax (daily for 21 days), or RT plus venetoclax, when tumors were ~50mm 3 ). N = 9–10 mice/group, additional statistics in text.

    Article Snippet: Human cell lines Ramos, Jeko-1, JVM-2, Rec-1, SU-DHL-4, and SU-DHL-8 were obtained from the American Type Culture Collection (ATCC) between 2006 and 2014; OCI-Ly3 and OCI-Ly19 were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) in 2014; and HT, Pfeiffer, Ri-1, SU-DHL-6, U2932, and WSU-FSCCL were generous gifts from Gilead Sciences in 2014.

    Techniques: Mouse Assay, Irradiation

    PRIT synergizes with venetoclax to cure up to 100% of mice bearing B-NHL xenografts Mice implanted with subcutaneous xenografts of A. Rec-1 (MCL) or B. U2932 (ABC-DLBCL) were treated with drug diluent only (control), PRIT (CD20-pretargeted RIT using 90 Y), venetoclax (daily for 21 days), or PRIT plus venetoclax, when tumors were ~50mm 3 ). N = 8–10/group, additional statistics in text.

    Journal: Cancer research

    Article Title: Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

    doi: 10.1158/0008-5472.CAN-17-0082

    Figure Lengend Snippet: PRIT synergizes with venetoclax to cure up to 100% of mice bearing B-NHL xenografts Mice implanted with subcutaneous xenografts of A. Rec-1 (MCL) or B. U2932 (ABC-DLBCL) were treated with drug diluent only (control), PRIT (CD20-pretargeted RIT using 90 Y), venetoclax (daily for 21 days), or PRIT plus venetoclax, when tumors were ~50mm 3 ). N = 8–10/group, additional statistics in text.

    Article Snippet: Human cell lines Ramos, Jeko-1, JVM-2, Rec-1, SU-DHL-4, and SU-DHL-8 were obtained from the American Type Culture Collection (ATCC) between 2006 and 2014; OCI-Ly3 and OCI-Ly19 were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) in 2014; and HT, Pfeiffer, Ri-1, SU-DHL-6, U2932, and WSU-FSCCL were generous gifts from Gilead Sciences in 2014.

    Techniques: Mouse Assay

    Anti-BCMA CAR T cells elicit potent reactivity against BCMA+ MM and lymphoma cell lines. (A) CAR T-cell cytolytic activity to the BCMA+, CD19– MM (RPMI-8226, NCI-H929, and U266-B1) or the BCMA+, CD19+ lymphoma (Burkitt lymphoma [BL]:Daudi, MCL:JeKo-1) cell lines. Anti-CD19 CAR T cells served as controls. Data are the average of two experiments using three unique donors, with the individual data points determined in triplicate. (B) The number of BCMA molecules per cell line was quantified as receptor density (•, left axis ), and correlated to anti-BCMA CAR T-cell IFN-γ release after 24 h of co-culture with the same cell line ( gray bars , right axis ). Error bars show standard error of the mean, representative of duplicate experiments.

    Journal: Human Gene Therapy

    Article Title: Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

    doi: 10.1089/hum.2018.001

    Figure Lengend Snippet: Anti-BCMA CAR T cells elicit potent reactivity against BCMA+ MM and lymphoma cell lines. (A) CAR T-cell cytolytic activity to the BCMA+, CD19– MM (RPMI-8226, NCI-H929, and U266-B1) or the BCMA+, CD19+ lymphoma (Burkitt lymphoma [BL]:Daudi, MCL:JeKo-1) cell lines. Anti-CD19 CAR T cells served as controls. Data are the average of two experiments using three unique donors, with the individual data points determined in triplicate. (B) The number of BCMA molecules per cell line was quantified as receptor density (•, left axis ), and correlated to anti-BCMA CAR T-cell IFN-γ release after 24 h of co-culture with the same cell line ( gray bars , right axis ). Error bars show standard error of the mean, representative of duplicate experiments.

    Article Snippet: REC-1 and JeKo-1 are mantle cell lymphoma (MCL) cell lines (ATCC; CRL-3004 and CRL-3006, respectively).

    Techniques: Activity Assay, Co-Culture Assay

    Proliferation and competition of aptamer-treated NHL cell lines. BAFF ligand can increase cell proliferation on binding to BAFF-R on B-cells. MTS assays were performed ( A–F ) to measure cell proliferation. Jeko-1 (A), Rec-1 (B), Z138 (C) and Granta-519 (D) cells were treated with increasing amounts of BAFF-R aptamers R-1, R-14 and R-22 or BAFF ligand. On 48 h post-incubation, MTS assays were performed, and cell proliferation was calculated in percentage and showed. (E–F) Cell proliferation was measured by MTS in Rec-1 (E) and Z138 (F) cells when treated with BAFF and increasing amounts of either R-1 or R-14 aptamers to investigate the potential of aptamers to block ligand-mediated proliferation.

    Journal: Nucleic Acids Research

    Article Title: Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells

    doi: 10.1093/nar/gkt125

    Figure Lengend Snippet: Proliferation and competition of aptamer-treated NHL cell lines. BAFF ligand can increase cell proliferation on binding to BAFF-R on B-cells. MTS assays were performed ( A–F ) to measure cell proliferation. Jeko-1 (A), Rec-1 (B), Z138 (C) and Granta-519 (D) cells were treated with increasing amounts of BAFF-R aptamers R-1, R-14 and R-22 or BAFF ligand. On 48 h post-incubation, MTS assays were performed, and cell proliferation was calculated in percentage and showed. (E–F) Cell proliferation was measured by MTS in Rec-1 (E) and Z138 (F) cells when treated with BAFF and increasing amounts of either R-1 or R-14 aptamers to investigate the potential of aptamers to block ligand-mediated proliferation.

    Article Snippet: Cell culture Rec-1 cells were purchased from ATCC and cultured in RPMI 1640 supplemented with 10% FBS and 1% glutamine.

    Techniques: Binding Assay, Incubation, Blocking Assay

    Streptomyces albus subsp. chlorinus NRRL B-24108 (left) and Streptomyces albus subsp. chlorinus JR1 (right) spores on MS agar medium.

    Journal: Marine Drugs

    Article Title: Novel Fredericamycin Variant Overproduced by a Streptomycin-Resistant Streptomycesalbus subsp. chlorinus Strain

    doi: 10.3390/md18060284

    Figure Lengend Snippet: Streptomyces albus subsp. chlorinus NRRL B-24108 (left) and Streptomyces albus subsp. chlorinus JR1 (right) spores on MS agar medium.

    Article Snippet: Here, we report the induction of a type II polyketide synthase (PKS) gene cluster in S. albus subsp. chlorinus , leading to overproduction of the novel compound fredericamycin C2 ( 1 ).

    Techniques:

    HPLC-MS analysis of crude extract from solid cultures of S. albus subsp. chlorinus JR1 ( a ) and its parental strain S. albus subsp. chlorinus NRRL B-24108 ( b ). ( A ) UV chromatogram. The asterisk ( * ) indicates the peak corresponding to fredericamycin C 2 ( 1 ) at t R = 12.7 min. ( B ) Mass spectrum associated with t R = 12.7 min from the UV chromatogram displayed in ( A ). ( C ) UV spectrum of purified fredericamycin C 2 ( 1 ).

    Journal: Marine Drugs

    Article Title: Novel Fredericamycin Variant Overproduced by a Streptomycin-Resistant Streptomycesalbus subsp. chlorinus Strain

    doi: 10.3390/md18060284

    Figure Lengend Snippet: HPLC-MS analysis of crude extract from solid cultures of S. albus subsp. chlorinus JR1 ( a ) and its parental strain S. albus subsp. chlorinus NRRL B-24108 ( b ). ( A ) UV chromatogram. The asterisk ( * ) indicates the peak corresponding to fredericamycin C 2 ( 1 ) at t R = 12.7 min. ( B ) Mass spectrum associated with t R = 12.7 min from the UV chromatogram displayed in ( A ). ( C ) UV spectrum of purified fredericamycin C 2 ( 1 ).

    Article Snippet: Here, we report the induction of a type II polyketide synthase (PKS) gene cluster in S. albus subsp. chlorinus , leading to overproduction of the novel compound fredericamycin C2 ( 1 ).

    Techniques: High Performance Liquid Chromatography, Purification

    Map of the genes encoded in BAC 2P5 isolated from a genomic library of S. albus subsp. chlorinus . Characters from A to K1 indicate the corresponding c2fdm gene described in Table 2 .

    Journal: Marine Drugs

    Article Title: Novel Fredericamycin Variant Overproduced by a Streptomycin-Resistant Streptomycesalbus subsp. chlorinus Strain

    doi: 10.3390/md18060284

    Figure Lengend Snippet: Map of the genes encoded in BAC 2P5 isolated from a genomic library of S. albus subsp. chlorinus . Characters from A to K1 indicate the corresponding c2fdm gene described in Table 2 .

    Article Snippet: Here, we report the induction of a type II polyketide synthase (PKS) gene cluster in S. albus subsp. chlorinus , leading to overproduction of the novel compound fredericamycin C2 ( 1 ).

    Techniques: BAC Assay, Isolation

    Proposed early biosynthesis steps of fredericamycin C 2 ( 1 ) in S. albus subsp. chlorinus .

    Journal: Marine Drugs

    Article Title: Novel Fredericamycin Variant Overproduced by a Streptomycin-Resistant Streptomycesalbus subsp. chlorinus Strain

    doi: 10.3390/md18060284

    Figure Lengend Snippet: Proposed early biosynthesis steps of fredericamycin C 2 ( 1 ) in S. albus subsp. chlorinus .

    Article Snippet: Here, we report the induction of a type II polyketide synthase (PKS) gene cluster in S. albus subsp. chlorinus , leading to overproduction of the novel compound fredericamycin C2 ( 1 ).

    Techniques: